Peritoneal metastases from extra-abdominal cancer – A population-based study

Flanagan, Michael; Solon, J.G.; Chang, Karen; Deady, Sandra; Moran, B.; Ra, Chisei; Shields, Conor; Mulsow, Jürgen

doi:10.1016/j.ejso.2018.07.049

Cited by 58 publications

(82 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another study showed the OS was 5.8 months in patients with BC PC from the metastasis PC was diagnosed as compared to 22.6 months in patients with no metastasis PC. Patients with synchronous metastases have signi cantly better survival than those with metachronous metastases [18].…”

Section: Discussionmentioning

confidence: 99%

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis from Breast Cancer: A Preliminary Report on 4 Cases

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Breast cancer (BC) has been ranked as the first malignancy most common and the fifth in mortality rate among women in China. Peritoneal metastases from BC is a rare disease and no guideline or international consensus for it. Objective: To summarise our experiences in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) to treat breast cancer peritoneal carcinomatosis (BC PC). Methods: 4 BC PC patients underwent CRS+HIPEC were enrolled in this study. The clinic-pathologic characteristics and overall survival (OS) were collected and analysed. Result: The average age at CRS+HIPEC was 59.8 years. The average time of CRS+HIPEC was 8.8 h. The median number of resected organ areas was 7. Overall survival from CRS+HIPEC were 31, 28, 16 and 52 months. There were no serious adverse events (SAEs) during the perioperative period. Conclusions: The 4 cases provided evidence that integrated therapy with CRS+HIPEC may be a promising strategy to improve the outcome for BC PC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis from Breast Cancer: A Preliminary Report on 4 Cases

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Peritoneal carcinomatosis arising from primary lung cancer is rare and is predominantly seen as a manifestation of intra‐abdominal malignancy, such as colorectal or ovarian cancer. Among all cases of peritoneal carcinomatosis originating from extra‐abdominal organs, 25.6% were lung cancer . Satoh et al reviewed the observations of 1041 lung cancer patients treated consecutively and found that 12 (1.2%) developed peritoneal involvement over the course of the disease .…”

Section: What Is New and Conclusionmentioning

confidence: 99%

“…Satoh et al reviewed the observations of 1041 lung cancer patients treated consecutively and found that 12 (1.2%) developed peritoneal involvement over the course of the disease . Despite recent medical and surgical advances, the survival of these patients was extremely poor, and the median survival time from the diagnosis of peritoneal carcinomatosis was 1.3 months . Peritoneal carcinomatosis sometimes causes paralytic or obstructive ileus, lending to difficulties in treatment secondary to poor patient tolerability of appropriate treatment due to poor PS.…”

Section: What Is New and Conclusionmentioning

confidence: 99%

“…1,2 Despite recent medical and surgical advances, the survival of patients suffering from this condition is extremely poor, and the median survival time from diagnosis is 1.3 months. 1 The majority of patients receive only palliative care because of their low performance status (PS). 3 Epidermal growth factor receptor (EGFR)-mutated lung cancer has a favorable prognosis, with a high response rate to EGFR-tyrosine kinase inhibitors (TKIs); consequently, EGFR-mutated lung cancer has a better overall survival time than other subtypes of lung cancer, despite the low PS of these patients.…”

Section: What Is Known and Objectivesmentioning

confidence: 99%

“…Among all cases of peritoneal carcinomatosis originating from extra-abdominal organs, 25.6% were lung cancer. 1 Satoh et al reviewed the observations of 1041 lung cancer patients treated consecutively and found that 12 (1.2%) developed peritoneal involvement over the course of the disease. 2 Despite recent medical and surgical advances, the survival of these patients was extremely poor, and the median survival time from the diagnosis of peritoneal carcinomatosis was 1.3 months.…”

Section: What Is New and Conclusionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical efficacy of osimertinib for a patient with ileus due to peritoneal carcinomatosis

Kawaguchi

Hanaoka

Hayashi

et al. 2020

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Education and Training in Peritoneal Surface Oncology

González‐Moreno,

Deraco,

Kusamura

et al. 2024

Journal of Surgical Oncology

View full text Add to dashboard Cite

Peritoneal surface oncology (PSO) is a novel field dealing with the knowledge of peritoneal neoplasms, primary or secondary, and their clinical management. As a specific treatment with curative intent for peritoneal neoplasms developed over the years, there is a growing need to comprehensively educate and train surgical oncologists worldwide in this discipline, a recognized unmet need. The European School of Peritoneal Surface Oncology (ESPSO) emerged in 2014 to provide an answer to this need.

show abstract

Peritoneal metastases from extra-abdominal cancer – A population-based study

Cited by 58 publications

References 35 publications

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis from Breast Cancer: A Preliminary Report on 4 Cases

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis from Breast Cancer: A Preliminary Report on 4 Cases

Clinical efficacy of osimertinib for a patient with ileus due to peritoneal carcinomatosis

Education and Training in Peritoneal Surface Oncology

Contact Info

Product

Resources

About